Status:
COMPLETED
Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects
Lead Sponsor:
Alizyme
Conditions:
Obesity
Eligibility:
All Genders
18-40 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate the amount of metabolites of ATL-962 in the blood and to investigate the effect of ATL-962 on the amount of fat that is excreted in the faeces in subjects w...
Detailed Description
Obesity is a significant and increasing clinical problem. There is a need for effective therapeutic agents to help people reduce weight. ATL-962 is a lipase inhibitor which could reduce the amount of ...
Eligibility Criteria
Inclusion
- Obese, otherwise-healthy subjects
- Body mass index 30-45kg/m2
Exclusion
- Women who are pregnant or breast feeding
- Any drug treatment within 2 weeks of commencement of dosing in this study
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00148382
Start Date
April 1 2005
End Date
July 1 2005
Last Update
April 11 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SFBCI
Miami, Florida, United States, 33181